To evaluate predictability, stability, efficacy, and safety of transepithelial photorefractive keratectomy (TPRK) using smart pulse technology (SPT) (SmartSurface procedure) of Schwind Amaris with mitomycin C for correction of post small incision lenticule extraction (SMILE) myopic residual refractive errors. This study is a prospective, non-comparative case series conducted at a private eye centre in Ismailia, Egypt, on eyes with post-SMILE myopic residual refractive errors because of undercorrection or suction loss (suction loss occurred after the posterior lenticular cut and the creation of side-cuts; redocking was attempted, and the treatment was completed in the same session with the same parameters) with myopia or myopic astigmatism. The patients were followed up post-SMILE for six months before the SmartSurface procedure, and then they were followed up for one year after that. TPRK were performed using Amaris excimer laser at 500 kHz. The main outcomes included refractive predictability, stability, efficacy, safety and any reported complications. This study included 68 eyes of 40 patients out of 1920 total eyes (3.5%) with post-SMILE technique myopic residual refractive errors. The average duration between the SMILE surgery and TPRK was 6.7 ± 0.4 months (range 6 to 8 months). The mean refractive spherical equivalent (SE) was within ± 0.50 D of plano correction in 100% of the eyes at 12 months post-TPRK. Astigmatism of < 0.50 D was achieved in 100% of the eyes. The mean of the residual SE error showed statistically significant improvement from preoperative − 1.42 ± 0.52 D to 0.23 ± 0.10 D (P < 0.0001). Uncorrected distance visual acuity (UDVA) (measured by Snellen's chart and averaged in logMAR units) was improved significantly to 0.1 ± 0.07 (P < 0.0001). UDVA was 0.2 logMAR or better in 100% of the eyes, 0.1 logMAR or better in 91.2% of the eyes, and 0.0 logMAR in 20.6% of the eyes. Corrected distance visual acuity (CDVA) remained unchanged in 79.4% of eyes. 14.7% of eyes gained one line of CDVA (Snellen). 5.9% of eyes gained two lines of CDVA (Snellen). Transepithelial photorefractive keratectomy using smart pulse technology with mitomycin C enhancement after SMILE is a safe, predictable, stable, and effective technique.

中文翻译：

---

SmartSurfACE 经上皮光屈光角膜切除术联合丝裂霉素 C 增强小切口微透镜提取后

使用 Schwind Amaris 的智能脉冲技术 (SPT) (SmartSurface 程序) 与丝裂霉素 C 评估经上皮光屈光角膜切除术 (TPRK) 的可预测性、稳定性、有效性和安全性，用于矫正小切口微透镜提取 (SMILE) 后近视残余屈光不正。这项研究是在埃及伊斯梅利亚的一家私人眼科中心进行的一项前瞻性、非比较性病例系列研究，研究对象是由于矫正不足或吸力损失（在后透镜状切割和创建侧切；尝试重新对接，并在同一疗程中以相同的参数完成治疗）患有近视或近视散光。在 SmartSurface 手术前对患者进行了六个月的 SMILE 后随访，然后他们被跟踪了一年。TPRK 使用 Amaris 准分子激光器在 500 kHz 下进行。主要结果包括屈光可预测性、稳定性、有效性、安全性和任何报告的并发症。这项研究包括 1920 只眼中 40 名患者的 68 只眼 (3.5%)，这些患者患有 SMILE 技术后近视残余屈光不正。SMILE 手术和 TPRK 之间的平均持续时间为 6.7 ± 0.4 个月（范围为 6 至 8 个月）。在 TPRK 后 12 个月，100% 的眼睛的平均屈光球当量 (SE) 在平面矫正的 ± 0.50 D 范围内。100% 的眼睛散光 < 0.50 D。残余 SE 误差的平均值显示出从术前 - 1.42 ± 0.52 D 到 0.23 ± 0.10 D (P < 0.0001) 的统计学显着改善。未矫正远视力 (UDVA)（通过 Snellen 图表测量并以 logMAR 单位平均）显着提高至 0.1 ± 0.07 (P < 0.0001)。UDVA 在 100% 的眼睛中为 0.2 logMAR 或更好，在 91.2% 的眼睛中为 0.1 logMAR 或更好，在 20.6% 的眼睛中为 0.0 logMAR。79.4% 的眼睛的矫正远视力 (CDVA) 保持不变。14.7% 的眼睛获得了一条 CDVA (Snellen)。5.9% 的眼睛获得了两条 CDVA (Snellen)。SMILE 后使用丝裂霉素 C 增强智能脉冲技术的经上皮屈光角膜切除术是一种安全、可预测、稳定和有效的技术。6%的眼睛。79.4% 的眼睛的矫正远视力 (CDVA) 保持不变。14.7% 的眼睛获得了一条 CDVA (Snellen)。5.9% 的眼睛获得了两条 CDVA (Snellen)。SMILE 后使用丝裂霉素 C 增强智能脉冲技术的经上皮屈光角膜切除术是一种安全、可预测、稳定和有效的技术。6%的眼睛。79.4% 的眼睛的矫正远视力 (CDVA) 保持不变。14.7% 的眼睛获得了一条 CDVA (Snellen)。5.9% 的眼睛获得了两条 CDVA (Snellen)。SMILE 后使用丝裂霉素 C 增强智能脉冲技术的经上皮屈光角膜切除术是一种安全、可预测、稳定和有效的技术。